(:CERC)

Aug 26, 2021 07:30 am ET
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and...
Aug 02, 2021 04:01 pm ET
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced recent business progress and...
Aug 02, 2021 07:30 am ET
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its...
Jul 27, 2021 08:30 am ET
Thinking about buying stock in Eyegate Pharmaceuticals, Mogu, Aditxt, Powerbridge Technologies, or Cerecor?
NEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EYEG, MOGU, ADTX, PBTS, and CERC.
Jul 26, 2021 04:01 pm ET
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced positive initial results from...
Jun 23, 2021 07:30 am ET
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into an...
Jun 07, 2021 07:00 am ET
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that it has entered into a debt financing agreement led by...
May 17, 2021 07:00 am ET
Cerecor to Participate in Upcoming Investor Conferences
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that members of its senior management team will participate...
May 13, 2021 07:00 am ET
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and first quarter 2021 financial...
May 11, 2021 07:00 am ET
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
May 05, 2021 07:00 am ET
Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that it has dosed its first patient in a Phase 1b open-label...
Mar 29, 2021 07:00 am ET
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that its wholly-owned subsidiary, Aevi Genomic Medicine, LLC...
Mar 08, 2021 04:01 pm ET
Cerecor Reports 2020 Financial Results and Provides Business Updates
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and year-end financial results for 2020....
Mar 04, 2021 07:00 am ET
Cerecor to Present at Upcoming Investor Conferences
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer,...
Mar 02, 2021 07:00 am ET
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day 28 in patients hospitalized with COVID-19...
Mar 01, 2021 07:00 am ET
Cerecor Appoints Schond L. Greenway as Chief Financial Officer
Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial...
Feb 02, 2021 07:00 am ET
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Jan 20, 2021 07:00 am ET
Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the exercise by the underwriters of their...
Jan 12, 2021 04:01 pm ET
Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previously announced underwritten...
Jan 07, 2021 10:03 pm ET
Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into an underwriting agreement with...
Jan 07, 2021 04:01 pm ET
Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common...
Jan 05, 2021 07:00 am ET
Cerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS
COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period)...
Dec 22, 2020 01:00 pm ET
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the...
Dec 16, 2020 07:00 am ET
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that it has dosed its first patient in a Phase 1b clinical trial...
Dec 08, 2020 07:00 am ET
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that its Investigational New Drug Application (IND) to study the...
Dec 01, 2020 07:00 am ET
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Nov 17, 2020 07:00 am ET
Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced a collaboration with The Frontiers in Congenital Disorders of...
Nov 09, 2020 04:01 pm ET
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and third quarter results for 2020....
Oct 12, 2020 07:00 am ET
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Gilla Kaplan, Ph.D., to the Board of...
Sep 10, 2020 07:00 am ET
Cerecor to Present at Upcoming Investor Conferences
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will...
Aug 26, 2020 07:00 am ET
Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease
Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced it has resumed the Phase 1b clinical study of CERC-002 in...
Aug 13, 2020 07:00 am ET
Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS
Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced the publication of a peer-reviewed paper demonstrating...
Aug 06, 2020 07:00 am ET
Cerecor Reports Second Quarter 2020 Financial Results and Business Update
Cerecor Inc. (NASDAQ : CERC), a leading biopharmaceutical company focused on development and commercialization of treatments for rare pediatric and orphan diseases, today announced recent business progress and second quarter results for 2020....
Aug 05, 2020 07:00 am ET
Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer,...
Aug 04, 2020 07:00 am ET
Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations
Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric...
Aug 03, 2020 07:00 am ET
Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations
Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
Jul 21, 2020 07:00 am ET
Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare pediatric and orphan diseases, today announced the first patient has been enrolled in a...
Jun 11, 2020 01:30 pm ET
Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today the closing of the previously announced underwritten...
Jun 09, 2020 09:05 am ET
Cerecor Inc. Announces Pricing of $33,000,000 Public Offering of Common Stock
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it has entered into an underwriting agreement with...
Jun 08, 2020 04:01 pm ET
Cerecor Inc. Announces Proposed Public Offering of Common Stock
Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common...
May 29, 2020 07:00 am ET
Cerecor to Present at the Jefferies Virtual Healthcare Conference
Cerecor Inc. (NASDAQ: CERC) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 2:30 p.m. EDT. A live webcast of the presentation...
May 28, 2020 07:00 am ET
Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that it has received clearance from the U.S. Food and...
May 26, 2020 07:00 am ET
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
Cerecor Inc. (NASDAQ: CERC) and Myriad Genetics Inc. (NASDAQ: MYGN) today announced that levels of novel cytokine, LIGHT, were highly correlated with disease severity and mortality in a COVID-19 acute respiratory distress syndrome (ARDS) biomarker...
May 07, 2020 06:30 am ET
Cerecor Reports Q1 2020 Results and Update
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced first quarter results for 2020. The Company...
May 04, 2020 09:15 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cerecor Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, May 4, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Cerecor Inc. (NASDAQ: CERC).
Apr 24, 2020 01:45 pm ET
Cerecor Announces Changes to Board of Directors
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Dr. Sol J. Barer has been appointed as the...
Mar 26, 2020 06:30 am ET
Cerecor Announces Exploration of the Role of an Inflammatory Cytokine, LIGHT, in COVID-19 Patients with Acute Lung Injury Leading to Acute Respiratory Distress Syndrome
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announces that it will explore the role of an inflammatory...
Mar 11, 2020 06:30 am ET
Cerecor Reports 2019 Results
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced full-year results for 2019.  The Company achieved...
Mar 06, 2020 09:00 am ET
Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Jeff Wilkins, MD  has joined the Company as its...
Feb 03, 2020 04:15 pm ET
Cerecor and Aevi Genomic Medicine Complete Merger
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today it has completed the previously announced acquisition...
Dec 05, 2019 08:45 am ET
Cerecor to Acquire Aevi Genomic Medicine
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan and rare diseases, as well as neurology announced today it has entered into a definitive merger...
Nov 14, 2019 06:30 am ET
Cerecor Reports Third Quarter 2019 Results
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases  and neurology, announced today its financial results for the third quarter ended September...
Nov 11, 2019 06:30 am ET
Cerecor Announces Clinical Updates on CERC-301 and CERC-802
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has achieved significant milestones in its clinical...
Nov 04, 2019 06:30 am ET
Cerecor Closes Deal to Sell Pediatric Portfolio
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it has closed the sale of its pediatric portfolio of...
Oct 14, 2019 06:30 am ET
Cerecor To Sell Pediatric Portfolio to AYTU BioScience
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for pediatric rare diseases and neurology, announced today that it has entered into an asset purchase agreement...
Aug 21, 2019 06:30 am ET
Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug...
Aug 08, 2019 04:05 pm ET
Cerecor Reports Second Quarter 2019 Results
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today its financial results for the second...
Jul 29, 2019 06:30 am ET
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has received notification...
Jul 15, 2019 06:30 am ET
Cerecor Announces First Patient Enrolled in CDG FIRST Trial
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced it has enrolled its first patient...
Jul 01, 2019 06:30 am ET
Cerecor Announces Positive Final Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (OH)
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive results from its completed...
Jun 28, 2019 06:30 am ET
Cerecor Added to Russell 3000® Index
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it has been added to the Russell...
Jun 12, 2019 04:05 pm ET
Cerecor Appoints Keith Schmidt to its Board of Directors
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to...
Jun 11, 2019 01:00 pm ET
Cerecor Set to Join Russell 3000® Index
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Russell...
May 09, 2019 04:05 pm ET
Cerecor Reports First Quarter 2019 Results
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today its financial results for the first...
Apr 29, 2019 06:30 am ET
Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has completed dosing in a...
Apr 18, 2019 08:20 am ET
Consolidated Research: 2019 Summary Expectations for Intec Pharma, Cerecor, Chiasma, Exela Technologies, PAVmed, and CUI Global — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Intec Pharma Ltd. (NASDAQ:NTEC), Cerecor Inc. (NASDAQ:CERC), Chiasma,...
Apr 15, 2019 06:30 am ET
Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)
ROCKVILLE, MD / ACCESSWIRE / April 15, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive interim results from the Phase I study of CERC-301, an NMDA receptor antagonist, being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in Parkinson's Disease.
Apr 11, 2019 06:30 am ET
Cerecor Announces Leadership Changes
ROCKVILLE, MD / ACCESSWIRE / April 11, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced changes to its executive leadership team, effective Monday, April 15, 2019. Dr. Simon Pedder, Ph.D. has been appointed Executive Chairman of the Board. As well, Patrick Crutcher has been promoted to Chief Strategy Officer. Peter Greenleaf will transition from the CEO role but remain on the Board of Directors, including provi
Mar 18, 2019 04:05 pm ET
Cerecor Reports Fourth Quarter and Full Year 2018 Results
-Significant Advancement in Pipeline and Regulatory Milestones-Meets Increased 2018 Revenue Guidance-Announces Net Revenue Guidance of $20-22 Million for 2019
Mar 11, 2019 09:15 am ET
Cerecor Announces Closing of $10.0 Million Bought Deal of Common Stock
ROCKVILLE, MD / ACCCESSWIRE / March 11, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today the closing of the previously announced underwritten offering of 1,818,182 shares of its common stock, at a price to the public of $5.50 per share (the "Public Price").
Mar 06, 2019 06:05 am ET
Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million
ROCKVILLE, MARYLAND / ACCESSWIRE / March 6, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 1,818,182 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). The closing of the offering is expected to occur o
Mar 05, 2019 05:30 pm ET
Cerecor Announces $8 Million Bought Deal Offering
ROCKVILLE MD / ACCESSWIRE / March 5, 2019 / Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 1,454,546 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). The closing of the offeri
Feb 19, 2019 08:27 am ET
Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug...
Feb 15, 2019 06:30 am ET
Cerecor Announces CERC-301 Granted U.S. Patent
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office...
Jan 28, 2019 06:30 am ET
Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate...
Jan 22, 2019 06:30 am ET
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the FDA has accepted its...
Jan 16, 2019 06:30 am ET
FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug...
Dec 13, 2018 07:00 am ET
Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of...
Nov 21, 2018 08:55 am ET
Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of KemPharm, Inc. (NASDAQ:KMPH), Bellerophon Therapeutics, Inc....
Nov 13, 2018 07:00 am ET
Cerecor Reports Third Quarter 2018 Results
Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and development capabilities, announced financial and operating results for the third quarter of 2018...
Oct 31, 2018 04:00 pm ET
Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted to the U.S....
Oct 30, 2018 04:00 pm ET
Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has been awarded Rare...
Sep 26, 2018 01:00 pm ET
Cerecor to Participate in Upcoming Healthcare Conferences
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today announced that the Company’s management will attend and host investor meetings at the upcoming...
Sep 25, 2018 06:30 am ET
Cerecor to Acquire Ichorion Therapeutics
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan disorders, announced today that it has agreed to acquire Ichorion Therapeutics, Inc. Ichorion is a...
Aug 31, 2018 07:00 am ET
Cerecor CEO to Present at the H.C. Wainwright Global Investment Conference
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on the near-term goal of becoming a leader in the U.S. pediatric market space, today announced that the Company’s management will present and host investor meetings at the H.C....
Aug 09, 2018 06:30 am ET
Cerecor Reports Second Quarter 2018 Financial Results
Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives of patients (“Cerecor” or the “Company”) today announced financial results...
Aug 01, 2018 06:30 am ET
Cerecor Announces First Patient Enrolled in Phase I Trial for Neurogenic Orthostatic Hypotension (nOH) in Parkinson’s Disease
Cerecor Inc. (NASDAQ: CERC), today announced that it has enrolled the first patient in a Phase I study of its proprietary drug candidate CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson’s disease.  The...
Jul 16, 2018 06:00 am ET
Cerecor Announces Expansion of Leadership Team
Cerecor Inc. (NASDAQ:CERC), today announced executive management changes that continue the Company’s strategic shift and further align its organizational structure to its long-term strategy.  Specifically, effective today, the Company announced the...
May 22, 2018 08:29 am ET
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock.  The offering closed on May...
May 17, 2018 08:01 am ET
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to...
May 11, 2018 08:15 am ET
Cerecor Reports First Quarter 2018 Financial Results
Cerecor Inc. (NASDAQ:CERC) (“Cerecor” or the “Company”) today announced financial results for the first quarter of 2018. Net revenues for the first quarter of 2018 were $4.5 million.  As of March 31, 2018, the Company had $65.4 million in total...
Apr 09, 2018 08:00 am ET
Cerecor Appoints Simon Pedder to its Board of Directors
Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors."We are delighted to welcome Dr. Pedder to our Board." said Dr. Uli Hacksell, Chairman of the Board of Cerecor, "With his...
Apr 02, 2018 08:00 am ET
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017
Cerecor Inc. (NASDAQ: CERC) today announced financial results for the fourth quarter and full year 2017. Net Revenues for the year ended 2017 were $27.8 million. As of December 31, 2017, the Company had $43.1 million in total assets including cash...
Mar 28, 2018 08:00 am ET
Cerecor Appoints Peter Greenleaf as Chief Executive Officer
Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company's board since May 2017. He brings to Cerecor over two decades of...
Feb 12, 2018 09:07 am ET
Cerecor to Acquire Avadel Pharmaceuticals' Pediatric Assets
Cerecor, Inc. (NASDAQ: CERC) today announced it has entered into definitive agreements with Avadel U.S. Holdings, Inc., and certain of its subsidiaries, to purchase and acquire all rights to Avadel's marketed pediatric products. The acquired...
Nov 17, 2017 08:30 am ET
Cerecor Announces Leadership Changes
Cerecor, Inc. (NASDAQ: CERC), a biopharmaceutical company focused on developing and commercializing innovative therapies that make a difference in the lives of patients, today announced key leadership changes, following the Company's recent...
Nov 17, 2017 08:15 am ET
Cerecor Acquires TRx Pharmaceuticals
Cerecor Inc. (NASDAQ: CERC) and TRx Pharmaceuticals, LLC (TRx) today announced that the companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals, LLC and its franchise of...
Nov 06, 2017 08:15 am ET
Cerecor Inc. Reports Third Quarter 2017 Financial Results
Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced its financial results for the third quarter of 2017."In the third quarter, we...
Oct 18, 2017 08:15 am ET
Cerecor, Inc. Regains Compliance with NASDAQ Minimum Bid Price Requirement
Cerecor, Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that it received a letter from the Nasdaq Listing Qualifications Staff (the...
May 30, 2017 08:30 am ET
Cerecor to present at the American Society for Clinical Psychopharmacology Conference
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Ronald Marcus MD, Chief Medical Officer,...
May 15, 2017 08:30 am ET
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Steven Boyd and Peter Greenleaf have joined...
May 09, 2017 08:30 am ET
Cerecor Inc. Reports First Quarter 2017 Financial Results
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the first quarter of...
May 01, 2017 08:30 am ET
Cerecor Reports Encouraging Topline Data from a NIH Sponsored Proof-of-Concept Trial of CERC-501 in Treatment-Resistant Depression
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced topline clinical results from a small,...
Apr 28, 2017 08:30 am ET
Cerecor Inc. Closes $5.0 Million Private Placement
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the closing of a $5.0 million private placement...
Mar 14, 2017 09:37 am ET
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the fourth quarter and...
Feb 07, 2017 09:32 am ET
Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has initiated a process to explore and...
Jan 27, 2017 04:20 pm ET
Cerecor Announces At-the-Market Equity Offering Program
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into an equity distribution...
Dec 05, 2016 08:00 am ET
Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced top-line clinical results from its nicotine...
Nov 29, 2016 04:01 pm ET
Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced top-line clinical results from its major...
Nov 08, 2016 09:16 am ET
Cerecor Inc. Reports Third Quarter 2016 Financial Results
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the...
Nov 07, 2016 02:35 pm ET
Discovery of Cerecor Drug Candidate CERC-611 (LY3130481) Published in Nature Medicine
Cerecor, Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders, today announced the publication of the rational...
Mar 17, 2016 09:00 am ET
Laidlaw & Co. Analyst Jim Molloy Interviewed by The Life Sciences Report
After a devastating start to 2016, biotech stocks have snapped back. Laidlaw & Co. analyst Jim Molloy likes the resurgence he's seeing in biotechnology share prices, but cautions that confirmation of a recovery will require cash-laden drug...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.